Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886220 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
A Phase 4 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
NCT03886220 is a Phase 4 study that has completed, run by AbbVie. The registered enrollment target is 82 participants.
The verdict
NCT03886220, a Phase 4 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
Study Summary
The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women. The primary hypothesis is that elagolix, compared to placebo, reduces HMB associated with uterine fibroids in premenopausal women.
Interventions
- DRUG Placebo
- DRUG Elagolix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2021-04-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03886220
The ClinicalTrials.gov registry entry for NCT03886220 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03886220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03886220 about?
NCT03886220 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women". The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women. The primary hypothesis is that elagolix, compared to placebo, reduces HMB associated with uterine fibr...
What is the current status of trial NCT03886220?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2019-04-12. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03886220?
The interventions under investigation include: Placebo (DRUG), Elagolix (DRUG).
Who is sponsoring clinical trial NCT03886220?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.